Market News AIOpen the app

SNDX stock news · Syndax Pharmaceuticals Inc.

Stories about Syndax Pharmaceuticals Inc. (SNDX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for SNDX

Follow Syndax Pharmaceuticals Inc. (SNDX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SNDX
Free on the App Store and Google Play, or on the web.
  1. Oct 13, 2026, 12:29 PM ET · Market

    Syndax Pharmaceuticals hit a setback after stopping work on a drug for lung disease.

    Bad for SNDX

    Syndax will stop testing axatilimab for IPF after a Phase 2 trial miss. Other work with the drug continues, but the lost use weakens the company's outlook.

  2. Oct 13, 2026, 8:28 AM ET · Market

    Syndax Pharmaceuticals, BioNTech, Seagate, and other major stocks dropped in value before the market opened on Tuesday.

    Bad for SNDX

    Syndax said its axatilimab lung-disease trial missed its main goal. That weakens the case for the treatment and is unfavorable for Syndax.

  3. Oct 12, 2026, 5:14 PM ET · Market

    12 health care companies saw big changes in their stock prices after the market closed on Monday.

    Neutral

    Syndax Pharmaceuticals shares fell about 17%. The roundup gives no company news explaining the move, so it does not show a change in the company's business outlook.